Broker's call: Aarti Drugs (Buy)

| Updated on May 19, 2020 Published on May 20, 2020

Anand Rathi

Aarti Drugs (Buy)

CMP: ₹766.7

Target: ₹1,028

Key takeaways: a) Aarti’s API sales were down 5 per cent to ₹400 crore as manufacturing and sales were curtailed in the last 10 days of Q4. Barring this, the company increased the proportion of antibiotics products to 44 per cent in FY20 (41 per cent in FY19), mainly due to higher ciprofloxacin, ofloxacin and norfloxacin sales.

b) Prices of key APIs rose 10-15 per cent as supplies from China have yet to resume in full swing. The company is evaluating contract manufacturing of products in shortage due to issues of supply from China. It expects prices to hold at these levels till global supplies are normal. Considering the new capacities and higher realisations we expect API revenue to register a 14.1 per cent CAGR over FY20-22.

c) In Q4 formulations grew 26.5 per cent to ₹49.5 crore, driven by export formulations as the company was establishing its marketing presence and filing products in different territories..

Valuation: Aarti Drugs is currently in a sweet spot as it will benefit from opportunities arising out of China and is the prime candidate to benefit from the government’s push for indigenous API manufacturing. We retain our ‘Buy’ rating, with a higher price target of ₹1,028, based on 12x FY22e EPS.

Risks: Delay in the ramp-up of the recently-added capacity; more-than-expected competition in generic APIs.

Published on May 20, 2020

A letter from the Editor

Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!


Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.